Pozelimab
( DrugBank: Pozelimab / KEGG DRUG: Pozelimab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 9 |
| 15 | Inclusion body myositis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 62 | Paroxysmal nocturnal hemoglobinuria | 27 |
11. Myasthenia gravis
Clinical trials : 525 / Drugs : 355 - (DrugBank : 80) / Drug target genes : 75 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
15. Inclusion body myositis
Clinical trials : 49 / Drugs : 73 - (DrugBank : 19) / Drug target genes : 14 - Drug target pathways : 134
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 380 / Drugs : 240 - (DrugBank : 38) / Drug target genes : 28 - Drug target pathways : 122
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|